Questions to answer below: Why is it imperative to write your NPI and DEA # on this script?  Why will you check the prescription monitoring program in your

 Questions to answer below:

Why is it imperative to write your NPI and DEA # on this script?

 Why will you check the prescription monitoring program in your state prior to prescribing?

What factors influence the prescribing of an extended release stimulant formulation over an immediate release formulation in the treatment of ADHD and what empirical evidence supports the efficacy and benefits of this choice?

Please answer all the questions above. And provide 2 7th edition APA scholarly references within 5 years. I have provided one reference below

Stahl, S.M. (2021). 
Stahl’s essential psychopharmacology: Prescribers guide (7th ed.). Cambridge University Press. ISBN: 9781108926010

Share This Post

Email
WhatsApp
Facebook
Twitter
LinkedIn
Pinterest
Reddit

Order a Similar Paper and get 15% Discount on your First Order

Related Questions

Neurotransmitter Table Neuro transmitter

Neurotransmitter Table Neuro transmitter Receptor Subtype Location/Function/Effects/symptoms of excess or deficit if applicable Distribution (ie: CNS/PNS, GI, vascular) Drug classes that target this neurotransmitter or receptor Specific medications that target this neurotransmitter or receptor Glutamate AMPA NMDA GABA GABA a GABA b Serotonin 5HT 5HT 1a 5HT 1B 5HT 1d

READ BELOW: 1. 1.  chose Atomoxetine for this patient.  2. List medication class and mechanism of action for the chosen medication. 1. According to Stahl

READ BELOW: 1. 1.  chose Atomoxetine for this patient.  2. List medication class and mechanism of action for the chosen medication. 1. According to Stahl (2021), this drug is a norepinephrine reuptake inhibitor and a selective norepinephrine inhibitor. Atomoxetine boosts norepinephrine/noradrenaline and increased dopamine in the prefrontal cortex. It also